WHAT IS CLAIMED IS:

1. A compound of Formula I



I

wherein

R^1 is selected from

1) hydrogen,
2) halogen,
3) substituted or unsubstituted C_1-C_{10} alkyl,
4) substituted or unsubstituted C_2-C_{10} alkenyl,
5) substituted or unsubstituted C_2-C_{10} alkynyl,
6) substituted or unsubsituted aryl,
7) substituted or unsubstituted C_3-C_{10} cycloalkyl,
8) substituted or unsubstituted heterocyclyl,
9) $-(CR^a_2)_nOR^4$, and
10) $-(CR^a_2)_tC(O)OR^4$;

said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more of R^7;

R^2 is selected from

1) hydrogen,
2) substituted or unsubstituted aralkyl,
3) substituted or unsubstituted C_1-C_{10} alkyl,
4) substituted or unsubstituted heterocyclyl,
5) substituted or unsubstituted aryl, and
6) substituted or unsubstituted C_3-C_{10} cycloalkyl;

R^3 is selected from

1) hydrogen,
2) halogen,
3) $-C(O)R^4$,
4) substituted or unsubstituted C_1-C_{10} alkyl,
5) substituted or unsubstituted aryl,
6) substituted or unsubstituted heterocyclyl,
7) substituted or unsubstituted C_3-C_{10} cycloalkyl,
8) substituted or unsubstituted C_2-C_{10} alkenyl, and
9) substituted or unsubstituted C_2-C_{10} alkynyl;

R^4 is independently selected from

1) hydrogen,
2) substituted or unsubstituted C_1-C_{10} alkyl,
3) substituted or unsubstituted aryl,
4) substituted or unsubstituted heterocyclyl,
5) substituted or unsubstituted C_3-C_{10} cycloalkyl,
6) substituted or unsubstituted C_2-C_{10} alkenyl, and
7) substituted or unsubstituted C_2-C_{10} alkynyl;

R^6 is independently selected from

1) substituted or unsubstituted aryl,
2) substituted or unsubstituted heterocyclyl,
3) substituted or unsubstituted cycloalkyl, and
4) halogen;

R^7 is independently selected from

1) hydrogen,
2) halogen,
3) substituted or unsubstituted C_1-C_{10} alkyl,
4) substituted or unsubstituted C_2-C_{10} alkenyl,
5) substituted or unsubstituted C_2-C_{10} alkynyl,
6) substituted or unsubstituted C_3-C_{10} cycloalkyl,
7) substituted or unsubstituted aryl,

8) substituted or unsubstituted heterocyclyl,
9) $-NO_2$,
10) $-NR_4(CR^a_2)_nC(O)R^4$,
11) $-(CR^a_2)_nNR^4_2$,
12) $-(CR^a_2)_nNR^4(CR^a_2)_nR^6$,
13) –CN,
14) $-(CR^a_2)_nC(O)R^4$,
15) $-(CR^a_2)_nC(O)(CR^a_2)_nOR^4$,
16) $-(CR^a_2)_nOR^4$,
17) $-(CR^a_2)_nR^6$,
18) $-(CR^a_2)_nC(O)OR^4$, and
19) $-(CR^a_2)_nSi(R^4)_3$;

R^a is independently selected from

1) hydrogen,
2) substituted or unsubstituted C_1-C_{10} alkyl,
3) substituted or unsubstituted C_2-C_{10} alkenyl,
4) substituted or unsubstitute C_2-C_{10} alkynyl,
5) $-OR^4$,
6) $-C(O)OR^4$,
7) $-NR^4_2$,
8) substituted or unsubstituted aryl,
9) substituted or unsubstituted heterocyclyl, and
10) substituted or unsubstituted C_3-C_{10} cycloalkyl;

n is independently 0 to 6;
t is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to Claim 1,

wherein

R^1 is selected from

1) hydrogen,

2) halogen,
3) substituted or unsubstituted C_1-C_6 alkyl,
4) substituted or unsubstituted C_2-C_{10} alkynyl,
5) substituted or unsubsituted aryl,
6) substituted or unsubstituted C_3-C_{10} cycloalkyl, and
7) substituted or unsubstituted heterocyclyl;

said alkyl, alkynyl, aryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more of R^7;

R^2 is selected from

1) substituted or unsubstituted aralkyl,
2) substituted or unsubstituted C_1-C_6 alkyl,
3) substituted or unsubstituted aryl, and
4) substituted or unsubstituted C_3-C_{10} cycloalkyl;

R^3 is selected from

1) halogen,
2) $-C(O)R^4$, and
3) substituted or unsubstituted C_1-C_6 alkyl;

R^4 is independently selected from

1) hydrogen,
2) substituted or unsubstituted C_1-C_6 alkyl,
3) substituted or unsubstituted aryl,
4) substituted or unsubstituted heterocyclyl, and
5) substituted or unsubstituted C_3-C_{10} cycloalkyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound according to Claim 2,

wherein

R^1 is selected from

1) substituted or unsubstituted C_1-C_6 alkyl,
2) substituted or unsubstituted C_2-C_{10} alkynyl,

3) substituted or unsubstituted heterocyclyl and
4) substituted or unsubstituted aryl;

said alkyl, alkynyl, heterocyclyl and aryl is optionally substituted with one or more of R^7;

R^2 is selected from

1) substituted or unsubstituted aralkyl, and
2) substituted or unsubstituted C_1-C_6 alkyl;

R^3 is selected from

1) halogen, and
2) $-C(O)R^4$;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. A compound of Formula II



II

wherein

R^1 is selected from

1) hydrogen,
2) halogen,
3) substituted or unsubstituted C_1-C_6 alkyl,
4) substituted or unsubstituted C_2-C_{10} alkynyl,
5) substituted or unsubstituted aryl,
6) substituted or unsubstituted C_3-C_{10} cycloalkyl, and
7) substituted or unsubstituted heterocyclyl;

said alkyl, alkynyl, aryl, cycloalkyl and heterocyclyl is optionally substituted with one or more of R^7;

R^2 is selected from

1) substituted or unsubstituted aralkyl, and
2) substituted or unsubstituted C_1-C_6 alkyl;

R^4 is independently selected from

1) hydrogen,
2) substituted or unsubstituted C_1-C_{10} alkyl,
3) substituted or unsubstituted aryl,
4) substituted or unsubstituted heterocyclyl,
5) substituted or unsubstituted C_3-C_{10} cycloalkyl,
6) substituted or unsubstituted C_2-C_{10} alkenyl, and
7) substituted or unsubstituted C_2-C_{10} alkynyl;

R^6 is independently selected from

1) substituted or unsubsituted aryl,
2) substituted or unsubstituted heterocyclyl,
3) substituted or unsubstituted C_3-C_{10} cycloalkyl, and
4) halogen;

R^7 is independently selected from

1) hydrogen,
2) halogen,
3) substituted or unsubstituted C_1-C_{10} alkyl,
4) substituted or unsubstituted C_2-C_{10} alkenyl,
5) substituted or unsubstituted C_2-C_{10} alkynyl,
6) substituted or unsubstituted C_3-C_{10} cycloalkyl,
7) substituted or unsubstituted aryl,
8) substituted or unsubstituted heterocyclyl,
9) $-NO_2$,
10) $-NR^4(CR^a{}_2)_nC(O)R^4$,
11) $-(CR^a{}_2)_nNR^4{}_2$,
12) $-(CR^a{}_2)_nNR^4(CR^a{}_2)_nR^6$,
13) $-CN$,
14) $-(CR^a{}_2)_nC(O)R^4$,

15) $-(CR^a_2)_nC(O)(CR^a_2)_nOR^4$,
16) $-(CR^a_2)_nOR^4$,
17) $-(CR^a_2)_nR^6$,
18) $-(CR^a_2)_nC(O)OR^4$, and
19) $-(CR^a_2)_nSi(R^4)_3$;

R^a is independently selected from

1) hydrogen,
2) substituted or unsubstituted C_1-C_{10} alkyl,
3) substituted or unsubstituted C_1-C_{10} alkenyl,
4) substituted or unsubstitute C_1-C_{10} alkynyl,
5) $-OR^4$,
6) $-C(O)OR^4$,
7) $-NR^4_2$,
8) substituted or unsubstituted aryl,
9) substituted or unsubstituted heterocyclyl, and
10) substituted or unsubstituted C_3-C_{10} cycloalkyl;

n is independently 0 to 6;
t is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. A compound selected from:

benzyl 4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2,5-diiodo-1H-pyrrole-3-carboxylate;

methyl 5-(4-fluorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-thien-2-yl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[3-(trimethylsilyl)prop-1-ynyl]-1H-pyrrole-3-carboxylate;

4'-benzyl 1-tert-butyl 3'-ethyl-5'-formyl-1H,1'H-2,2'-bipyrrole-1,4'-dicarboxylate;

benzyl 5-(3,5-dimethylisoxazol-4-yl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(1-benzofuran-2-yl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(3-nitrophenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(5-methyl-2-furyl)-1H-pyrrole-3-carboxylate;

benzyl 5-[3-(acetylamino)phenyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate;

benzyl 5-(3-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(3-methoxyphenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(5-formyl-2-furyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(phenylethynyl)-1H-pyrrole-3-carboxylate;

methyl 5-{3-[benzyl(methyl)amino]prop-1-ynyl}-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(2-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(4-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(2-methoxyphenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(4-methoxyphenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(2-methylphenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(3-methylphenyl)-1H-pyrrole-3-carboxylate;

benzyl 5-(2-chlorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(3-chlorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[1-(3-hydroxypropyl)vinyl]-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(5-hydroxypent-1-ynyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclohexyl)ethynyl]-1H-pyrrole-3-carboxylate;

methyl 5-[3-(dimethylamino)prop-1-ynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(3,3-dimethylbut-1-ynyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(pyridin-2-ylethynyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-methoxyprop-1-ynyl)-1H-pyrrole-3-carboxylate;

methyl 5-[(2-bromophenyl)ethynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-[3-(1H-1,2,3-benzotriazol-1-yl)prop-1-ynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-5-(2-ethylbutyl)-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(6-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 5-(4-tert-butylphenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(2,4-difluorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[3-(methoxycarbonyl)phenyl]-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[4-(methoxycarbonyl)phenyl]-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclopentyl)ethynyl]-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-hydroxy-3-methylbut-1-ynyl)-1H-pyrrole-3-carboxylate

methyl 4-ethyl-2-formyl-5-(1-hexylvinyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(1,3-thiazol-2-yl)-1H-pyrrole-3-carboxylate;

methyl 5-[1-(3-chloropropyl)vinyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(5-chloropent-1-ynyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-hydroxy-3-phenylbut-1-ynyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-isopentyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-methylthien-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-isobutyl-1H-pyrrole-3-carboxylate;

methyl 5-cyclohexyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-butyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-cyclopentyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(cyclohexylmethyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-sec-butyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-methoxy-2-methyl-3-oxopropyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(2-methoxyphenyl)-1H-pyrrole-3-carboxylate;

or a pharmaceutically acceptable salt or stereoisomer thereof.

6. The compound according Claim 5 that is selected from

methyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate



;

benzyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate



;

methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclohexyl)ethynyl]-1H-pyrrole-3-carboxylate



;

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate



;

methyl 5-[1-(3-chloropropyl)vinyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate



;

or a pharmaceutically acceptable salt or stereoisomer thereof.

7. A trifluoroacetic acid salt of a compound of Claim 5 which is selected from

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(6-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate.

8. A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

9. A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

10. The method of Claim 9 wherein the protein kinase is an RTK.

11. The method of Claim 10, wherein the RTK is selected from IR, IGF-1R and IRR.

12. A method of treating a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

13. A method of Claim 12, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

1) cancer,
2) diabetes,
3) an autoimmune disorder,
4) a hyperproliferation disorder,
5) aging,
6) acromegaly, and

7) Crohn's disease.

14. A method of preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

15. A method of Claim 14, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

1) cancer,
2) diabetes,
3) an autoimmune disorder,
4) a hyperproliferation disorder,
5) aging,
6) acromegaly, and
7) Crohn's disease.

16. A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

17. A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

18. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) a retinoid receptor modulator,
4) a cytotoxic/cytostatic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,

9) a reverse transcriptase inhibitor,
10) an angiogenesis inhibitor,
11) a PPAR-γ agonist,
12) a PPAR-δ agonists,
13) an inhibitor of cell proliferation and survival signaling, and
14) an agent that interferes with a cell cycle checkpoint.

19. The method of Claim 18, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

20. A method of preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) a retinoid receptor modulator,
4) a cytotoxic/cytostatic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor,
10) an angiogenesis inhibitor,
11) a PPAR-γ agonist,
12) a PPAR-δ agonists,
13) an inhibitor of cell proliferation and survival signaling, and
14) an agent that interferes with a cell cycle checkpoint.

21. The method of Claim 20, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

22. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

23. The method of Claim 22 wherein radiation therapy is also administered.

24. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

25. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

26. The method of Claim 26 wherein the GPIIb/IIIa antagonist is tirofiban.

27. A method of preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

28. The method of Claim 27 wherein the GPIIb/IIIa antagonist is tirofiban.

29. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.

30. A method of preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.